Single-cell RNA and TCR sequencing of tumor-infiltrating lymphocytes and draining lymph node immune cells following AMP-410 treatment

AMP-410 is a bifunctional VEGF-4-1BB biologic designed to simultaneously target VEGF and 4-1BB pathways, delivering a localized and synergistic approach to cancer immunotherapy. This study demonstrates that dual targeting of VEGF and 4-1BB signaling normalizes the tumor microenvironment, prevents T cell exhaustion in the TME in the later stage and also reduce the T cell conal exchange between tumor microenvironment and draining lymph nodes (dLNs), suggesting a local activity.